CN104099333A - 用于乳腺癌的piRNA - Google Patents
用于乳腺癌的piRNA Download PDFInfo
- Publication number
- CN104099333A CN104099333A CN201410247837.6A CN201410247837A CN104099333A CN 104099333 A CN104099333 A CN 104099333A CN 201410247837 A CN201410247837 A CN 201410247837A CN 104099333 A CN104099333 A CN 104099333A
- Authority
- CN
- China
- Prior art keywords
- pirna
- breast cancer
- sno75
- expression
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 39
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 39
- 108091007412 Piwi-interacting RNA Proteins 0.000 title claims abstract description 30
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 20
- 230000014509 gene expression Effects 0.000 abstract description 15
- 210000001519 tissue Anatomy 0.000 abstract description 12
- 238000000636 Northern blotting Methods 0.000 abstract description 6
- 239000002243 precursor Substances 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 4
- 108020003224 Small Nucleolar RNA Proteins 0.000 abstract description 3
- 102000042773 Small Nucleolar RNA Human genes 0.000 abstract description 3
- 238000001415 gene therapy Methods 0.000 abstract description 3
- 239000013604 expression vector Substances 0.000 abstract description 2
- 210000003917 human chromosome Anatomy 0.000 abstract description 2
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种用于乳腺癌的piRNA，其来自人乳腺癌细胞，包含SEQIDNO.1所示序列，定位于人染色体1q25，其前体序列为snoRNA。Northernblot和定量RT-PCR检测结果表明该piRNA在乳腺癌组织中低表达。本发明提供的piRNA可用于制备治疗乳腺癌疾病的药物。例如，采用基因治疗的方法，以质粒或者病毒为表达载体，使其在癌变部位高效表达。
Description
技术领域
本发明属于分子生物学及生物医药技术领域，涉及人源piRNA寡核苷酸序列以及其在制备治疗乳腺癌疾病药物中的用途。
背景技术
piRNA（PIWI-interacting RNA）是一类具有26～32nt的RNA分子，经由其前体分子在酶的作用下加工生成的，其前体序列一般为长链非编码RNA（long non-coding RNA, lncRNA），目前认为piRNA的功能是参与生命的一些基本过程，如分化发育等，越来越多的证据表明piRNA在细胞中起着调控基因表达的重要作用。最近的研究发现piRNA与肿瘤的发生发展有紧密的相关性，一些piRNA可以显著的抑制肿瘤生长。肿瘤相关的piRNA的发现可能会对肿瘤的基因治疗产生重大的影响。通过对肿瘤和正常组织的小RNA高通量测序分析，可以鉴定肿瘤相关的piRNA，通过引入对肿瘤细胞过表达小RNA可以有效抑制肿瘤的生长。因此，发现肿瘤细胞中的piRNA 以及基于piRNA的肿瘤治疗具有十分重要的意义。
近四十年来关于肿瘤学的大量而迅速的研究，极大扩展了我们对于肿瘤理解的深入程度以及复杂性。肿瘤疾病涉及到整个基因组动态改变的复杂过程，比如各种突变引起的抗癌基因与促癌基因功能的紊乱。乳腺癌是全球高发肿瘤类型之一。尽管目前一些治疗手段可以帮助大多数肿瘤患者缓解痛苦，但乳腺癌仍极大威胁着女性生命安全，导致生活质量下降。每一年，全世界范围内有超过一百三十万的乳腺癌新发病例，有四十五万人死于此病症。建立发现更多的新的可以用于乳腺癌预防及治疗的靶点有重大意义，也仍面临着巨大挑战。
发明内容
本发明的目的是提供一种piRNA寡核苷酸序列及其在制备治疗乳腺癌疾病药物中的用途。
本发明以人乳腺癌和癌旁组织为材料进行deep-sequencing 的小分子RNA高通量测序以及mRNA芯片表达谱分析，采用分子生物学以及生物信息学常规技术进行试验以及分析，得到了一条28nt的RNA分析，经过Blast比对，Northern blot杂交，及RNA共沉淀实验得到证实其为piRNA分子，命名为pi-sno75。Pi-sno75是由其前体snoRNA75在细胞内经过加工后形成的成熟体，经过基因序列的同源性分析获得snoRNA的前体RNA序列。此外，针对该piRNA序列设计其2’-O-甲基化修饰的化学合成小分子RNA，并研究其对乳腺癌细胞生长的影响进行了分析。
本发明所提供的piNA来自人乳腺癌细胞，成熟piRNA序列长度为28nt，其前体序列为snoRNA。Northern blot和定量RT-PCR检测结果表明该piRNA在乳腺癌组织中低表达。构建pi-sno75高表达的乳腺癌细胞系，结果表明在与多柔比星联用条件下，可以显著抑制乳腺癌细胞的生长增殖。基于上述工作本发明得以完成。
具体的说，本发明所提供的人源piRNA——pi-sno75包含如下序列：5’-GGGAUUUCUGAAAUUCUAUUCUGAGGCU-3’ ，定位于人染色体1q25。其中，序列中的U可用T替换。
本发明所提供的人源piRNA可采用化学合成的方法得到，为增强其稳定性，生物利用度等药学特征，可对其进行氧甲基化修饰。
本发明提供的piRNA可用于制备治疗乳腺癌疾病的药物。例如，采用基因治疗的方法，以质粒或者病毒为表达载体，使其在癌变部位高效表达。
附图说明
图1、Northern blot检测pi-sno75在乳腺癌组织中的表达；
图2、定量PCR检测pi-sno75在乳腺癌及癌旁组织中的表达；
图3、过表达pi-sno75及联合应用多柔比星抑制MCF7细胞的增殖（其中A为过表达pi-sno75对MCF7细胞增殖的抑制作用，B为过表达pi-sno75及联合应用多柔比星对MCF7细胞增殖的抑制作用）；
图4、pi-sno75过表达细胞系在体内与多柔比星联合给药对乳腺癌的抑制效果。
具体实施方式
下面结合实施例对本发明作进一步的说明，但并不局限于此。
实验一 乳腺癌组织以及癌旁组织的deep-sequencing 以及乳腺癌中pi-sno75表达的Northern blot验证
我们从中山大学附属第一医院女性乳腺癌患者术后摘除肿瘤组织中，分离500mg肿瘤组织以及200mg癌旁组织。分离后液氮冷冻保存。研磨均匀的组织 (<100 mg)加1mL Trizol溶解，吹打至散，室温放置5分钟；加氯仿200μl，剧烈振荡60秒；静置5分钟，然后4℃，12000g，离心15分钟；转移上清到新的EP管中，加异丙醇500μl，混匀，放置10分钟；4℃，12000g，离心10分钟；弃上清，加75％乙醇1000μl，洗两次，4℃，12000g，离心5分钟； 弃上清，室温干燥。用DEPC水溶解RNA，检测纯度和浓度。样品合格后，寄到深圳华大基因公司做小分子RNA深度测序，测定小分子RNA长度范围是18-40bp。测序结果由华大公司进行分析比对。其中得到一条来自snoRNA75的piRNA序列（如SEQ ID NO.1所示），命名为pi-sno75。长度为28nt。以【γ-32P】ATP标记pi-sno75反向互补LNA杂交检测探针，按照常规Northern blot方法检测pi-sno75在人乳腺癌细胞中的表达。由图1可知，pi-sno75在乳腺癌组织的中确实有表达。
实验二 乳腺癌组织以及癌旁组织中pi-sno75表达情况分析
以乳腺癌组织以及对应癌旁组织为材料，利用上述方法提取RNA，按照TakaraRT反转录试剂盒进行反转录试验，cDNA产物利用Takara SYBR real-time试剂盒进行定量PCR检测。GAPDH作为内参。成对T-test进行统计学分析。由图2可知，pi-sno75在乳腺癌的表达较其癌旁组织中的表达要低。
实验三 体外pi-sno75对乳腺癌细胞系MCF7诱导凋亡情况检测
人的MCF7细胞培养在10%血清浓度的DMEM（Dμlbecco's modified Eagle's medium）中。采用Lipofectamine RNAiMAX (Invitrogen)转染试剂进行小RNA转染。具体操作按照使用说明进行。转染后36h加入多柔比星5μM。MCF细胞用不含EDTA的胰酶消化收集，用PBS洗涤细胞二次（2000rpm离心5min）收集1～5×105细胞；加入500μL的Binding Buffer悬浮细胞；加入5μL Annexin V-FITC混匀后，加入5 μL Propidium Iodide，混匀；室温、避光、反应5～15min，然后进行流式细胞仪的观察和检测（激发波长Ex=488 nm；发射波长Em=530 nm；荧光补偿调节：使用未经凋亡诱导处理的正常细胞，作为对照进行荧光补偿调节去除光谱重叠和设定十字门的位置），结果显示在多柔比星存在条件下，pi-sno75显著引起凋亡（见图3）。
实验四 体内pi-sno75对乳腺癌细胞系MCF7诱导凋亡情况检测
构建过表达pi-sno75的乳腺癌细胞系，利用上边的质粒，包含pi-sno75的内含子片段插入在慢病毒载体中，其位置处于CMV启动子之后，ires-gfp之前。构建好的pHIV-cPPT-GFP-pi-sno75与空白载体，分别同pCMV-?R8.2 和pCMV-VSV-G共转染HEK293T包装假病毒，之后用PEG6000浓缩病毒，感染MCF7细胞。流式分选GFP阳性细胞（FACS Aria II ，Becton Dickinson），培养扩增。选择5周龄左右的雌性NOD/SCID小鼠，在同一只小鼠的左右两侧乳腺组织附近分别注射等量过表达的pi-sno75细胞系与对照载体细胞系。当成瘤直径大小在5mm左右时，每周通过小鼠尾静脉注射doxorubicin（2mg/kg）。给药后，肿瘤的生长速度变慢，在首次给药四周后，我们从小鼠体内取出肿瘤及称量湿重。Pi-sno75过表达的细胞系成瘤大小比空白载体显著性的小，且质量轻（见图4）。
综合细胞实验与动物模型实验，pi-sno75在于抗肿瘤药物联合使用下，体内体外结果表明可以显著诱导乳腺癌凋亡并抑制肿瘤增殖。
<110> 中山大学
<120> 用于乳腺癌的piRNA
<130>
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 28
<212> RNA
<213> human
<400> 1
gggauuucug aaauucuauu cugaggcu 28
Claims (6)
1.一种piRNA，其包含如下序列：
5’-GGGAUUUCUGAAAUUCUAUUCUGAGGCU-3’（SEQ ID NO.1），其中，U可用T替换。
2.含有权利要求1所述piRNA的质粒或病毒载体。
3.权利要求1所述的piRNA在制备治疗乳腺癌疾病的制剂或药物中的应用。
4.权利要求1所述的piRNA和其他抗肿瘤药物联用在制备治疗乳腺癌疾病的制剂或药物中的应用。
5.根据权利要求4所述的应用，其特征在于，所述其他抗肿瘤药物为多柔比星。
6.权利要求2所述的质粒或病毒载体在制备治疗乳腺癌疾病的制剂或药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410247837.6A CN104099333B (zh) | 2014-06-05 | 2014-06-05 | 用于乳腺癌的piRNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410247837.6A CN104099333B (zh) | 2014-06-05 | 2014-06-05 | 用于乳腺癌的piRNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104099333A true CN104099333A (zh) | 2014-10-15 |
| CN104099333B CN104099333B (zh) | 2017-02-01 |
Family
ID=51667875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410247837.6A Expired - Fee Related CN104099333B (zh) | 2014-06-05 | 2014-06-05 | 用于乳腺癌的piRNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104099333B (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106916885A (zh) * | 2017-01-13 | 2017-07-04 | 青岛大学 | 用于检测心脏病的piRNA组合及其应用 |
| CN107190058A (zh) * | 2017-05-23 | 2017-09-22 | 苏州大学 | piRNA在治疗弥漫性大B细胞性淋巴瘤中的应用 |
| WO2018107381A1 (en) * | 2016-12-14 | 2018-06-21 | Shanghaitech University | Compositions and methods for treating cancer by inhibiting piwil4 |
| CN109072240A (zh) * | 2016-02-26 | 2018-12-21 | 耶鲁大学 | 使用piRNA诊断和治疗癌症的组合物和方法 |
| CN112646892A (zh) * | 2020-12-30 | 2021-04-13 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一组乳腺癌早期诊断的piRNA生物标志物及其应用 |
| CN113230268A (zh) * | 2021-05-10 | 2021-08-10 | 上海市东方医院（同济大学附属东方医院） | 一种非编码小rna基因、载体和细胞在制备抑制乳腺癌的药物中的用途 |
-
2014
- 2014-06-05 CN CN201410247837.6A patent/CN104099333B/zh not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| HUANG等: "Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer", 《CLIN TRANSL ONCOL》 * |
| JIA CHENG: "PiRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells", 《CLINICA CHIMICA ACTA》 * |
| LARA等: "The role of tumor initiating cells in drug resistance of breast cancer:Implications for future therapeutic approaches", 《DRUG RESISTANCE UPDATES》 * |
| 向阳等: "piRNA 在癌症上的研究进展", 《安徽农业科学》 * |
| 李培旺等: "新型非编码小RNA", 《生物化学与生物物理进展》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109072240A (zh) * | 2016-02-26 | 2018-12-21 | 耶鲁大学 | 使用piRNA诊断和治疗癌症的组合物和方法 |
| WO2018107381A1 (en) * | 2016-12-14 | 2018-06-21 | Shanghaitech University | Compositions and methods for treating cancer by inhibiting piwil4 |
| US10787666B2 (en) | 2016-12-14 | 2020-09-29 | Shanghaitech University | Compositions and methods for treating cancer by inhibiting PIWIL4 |
| CN106916885A (zh) * | 2017-01-13 | 2017-07-04 | 青岛大学 | 用于检测心脏病的piRNA组合及其应用 |
| CN106916885B (zh) * | 2017-01-13 | 2021-11-12 | 青岛大学 | 用于检测心脏病的piRNA组合及其应用 |
| CN107190058A (zh) * | 2017-05-23 | 2017-09-22 | 苏州大学 | piRNA在治疗弥漫性大B细胞性淋巴瘤中的应用 |
| CN112646892A (zh) * | 2020-12-30 | 2021-04-13 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一组乳腺癌早期诊断的piRNA生物标志物及其应用 |
| CN112646892B (zh) * | 2020-12-30 | 2022-02-01 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一组乳腺癌早期诊断的piRNA生物标志物及其应用 |
| CN113230268A (zh) * | 2021-05-10 | 2021-08-10 | 上海市东方医院（同济大学附属东方医院） | 一种非编码小rna基因、载体和细胞在制备抑制乳腺癌的药物中的用途 |
| CN113230268B (zh) * | 2021-05-10 | 2023-02-21 | 上海市东方医院（同济大学附属东方医院） | 一种非编码小rna基因、载体和细胞在制备抑制乳腺癌的药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104099333B (zh) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104099333A (zh) | 用于乳腺癌的piRNA | |
| Wang et al. | Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer | |
| Cui et al. | miR-146a inhibits proliferation and enhances chemosensitivity in epithelial ovarian cancer via reduction of SOD2 | |
| AU2015309403B2 (en) | Use of alphavirus in preparation of antitumor drugs | |
| Dhanasekaran et al. | Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC) | |
| Lum et al. | Gold (III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro | |
| Meng et al. | Downregulation of miR-33a-5p in hepatocellular carcinoma: a possible mechanism for chemotherapy resistance | |
| Mongre et al. | Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma | |
| Han et al. | MicroRNA-1251-5p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting AKAP12 | |
| Cui et al. | Isoliquiritigenin inhibits non-small cell lung cancer progression via m6A/IGF2BP3-dependent TWIST1 mRNA stabilization | |
| Wang et al. | The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells | |
| Esmatabadi et al. | Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells | |
| Sun et al. | Cation lipid-assisted PEG6-PLGA polymer nanoparticles encapsulated knocking down long ncRNAs reverse non-coding RNA of xist through the support vector machine model to regulate the molecular mechanisms of gastric cancer cell apoptosis | |
| Behbahani et al. | Breast cancer radioresistance may be overcome by osteopontin gene knocking out with CRISPR/Cas9 technique | |
| Bahreyni et al. | Synergistic viro-chemoimmunotherapy in breast Cancer enabled by Bioengineered Immunostimulatory exosomes and Dual-targeted Coxsackievirus B3 | |
| CN105969846B (zh) | 一种长非编码rna及其在诊断/治疗非小细胞肺癌中的应用 | |
| CN102102102A (zh) | hsa-miR-185的新用途 | |
| Lu et al. | MitoKATP regulating HIF/miR210/ISCU signaling axis and formation of a positive feedback loop in chronic hypoxia-induced PAH rat model | |
| Lu et al. | The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR | |
| Li et al. | Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism | |
| CN103893780B (zh) | 一种miR-100抑制剂在制备治疗乳腺癌药物中的应用 | |
| Wu et al. | MicroRNA let-7a: A novel therapeutic candidate in prostate cancer | |
| CN102352368B (zh) | Ing4与osm双基因共表达载体及其应用 | |
| CN109908160B (zh) | 黄夹次乙苷作为抗肿瘤药物的应用 | |
| Cui et al. | Identification of a Novel miR-146a-POU3F2/SMARCA5 Pathway in Glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170201 |